Glucose-dependent Insulinotropic Peptide (22-51) (human) (trifluoroacetate salt) (Synonyms: GIP (22-51),Gastric Inhibitory Peptide (22-51)) |
| カタログ番号GC91860 |
Glucose-dependent insulinotropic peptide (GIP) (22-51) is a pro-atherogenic 30-amino acid peptide corresponding to residues 22-51 of the GIP precursor protein proGIP that has been found in human plasma.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: N/A
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Glucose-dependent insulinotropic peptide (GIP) (22-51) is a pro-atherogenic 30-amino acid peptide corresponding to residues 22-51 of the GIP precursor protein proGIP that has been found in human plasma.[1] It induces IκB-α degradation and NF-κB nuclear translocation in macrophage-differentiated THP-1 cells and isolated human aortic endothelial cells when used at a concentration of 1 µM. In vivo, GIP (22-51) increases atherosclerotic lesion area and plaque formation in ApoE-/- mice.
References:
[1].Masaki, T., Kodera, Y., Terasaki, M., et al.GIP_HUMAN[22-51] is a new proatherogenic peptide identified by native plasma peptidomicsSci. Rep.11(1)14470(2021).
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *